Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has disclosed its provisional Q1 2025 consolidated financial results via fair disclosure, reporting revenue of KRW 1.298T (+37.11% YoY) and operating profit of KRW 486.7B (+119.92% YoY).
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: Provisional Operating Results Based on Consolidated Financial Statements (Fair Disclosure)
- Period Covered: Q1 2025 (Jan 1, 2025 – Mar 31, 2025)
- Consolidated Financial Summary (Unit: KRW million, %):
- Revenue: KRW 1,298,273 million (+3.33% QoQ, +37.11% YoY)
- Operating Profit: KRW 486,689 million (+49.45% QoQ, +119.92% YoY)
- Profit Before Income Tax: KRW 499,387 million (+33.52% QoQ, +108.01% YoY)
- Net Profit: KRW 375,554 million (+16.82% QoQ, +109.38% YoY)
- Net Profit Attributable to Owners of Parent: KRW 375,554 million (+16.82% QoQ, +109.38% YoY)
- Information Provision Details:
- Provider: IR Team
- Target Audience: Domestic and foreign investors, press, etc.
- Date & Time: April 23, 2025
- Other Important Details:
- Related materials will be published on the company website (http://www.samsungbiologics.com).
- The figures were prepared prior to completion of the external audit, thus subject to change depending on the audit results.
- Related Disclosure: April 09, 2025: Advance Notice of Financial Results Announcement
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Provisional Earnings Release and Upcoming Quarterly Report Filing
This disclosure provides notice of Samsung Biologics’ provisional consolidated financial results for Q1 2025 via fair disclosure.
Because these numbers were prepared prior to completion of the external audit, checking the final figures in the upcoming Q1 periodic report (quarterly report) and IR materials on the official website is essential.
Relevant details can be verified in the subsequent quarterly report filing and the IR section of the company’s official website.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
